Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9HE
|
|||
| Former ID |
DNCL001614
|
|||
| Drug Name |
BI 113823
|
|||
| Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01207973) Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee. U.S. National Institutes of Health. | |||
| REF 2 | The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.